In the paradigm of HER2-overexpressing breast cancer cell lines, namely SKBR3 and MDAMB-453, application of Leo has been empirically demonstrated to diminish the expression of STAT, JAK2, and Vascular Endothelial Growth Factor (VEGF). Here, VEGFA is linked to breast cancer.